Medpace Holdings (MEX:MEDP) Stock Based Compensation: MXN382 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MEDP Medpace Holdings Inc MEX:MEDP
95 GF Score
Price MXN7,022.03
GF Value MXN6,131.53
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Stock Based Compensation?

Medpace Holdings MEX:MEDP 95 Stock Based Compensation is MXN382 Mil as of Jun. 2026. GuruFocus rates MEX:MEDP with a GF Score™ of 95/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review.

Medpace Holdings's Stock Based Compensation for the three months ended in Jun. 2026 was MXN76 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was MXN382 Mil.

Medpace Holdings Stock Based Compensation Related Terms

Medpace Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Stock Based Compensation Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 296.82 417.45 348.24 532.11 626.35

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.05 115.99 101.19 88.69 75.87
MEX:MEDP
95GF Score
Medpace Holdings Inc MEX:MEDP
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN382 Mil.

What does a Stock Based Compensation of MXN382 Mil mean?
Medpace Holdings (MEX:MEDP) has a Stock Based Compensation of MXN382 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medpace Holdings and its competitors.
Is Medpace Holdings' Stock Based Compensation too high?
Medpace Holdings' current Stock Based Compensation is MXN382 Mil. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Stock Based Compensation compare to ICLR and RVTY?
Medpace Holdings' Stock Based Compensation of MXN382 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medpace Holdings and its competitors. Medpace Holdings's current Stock Based Compensation is MXN382 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current Stock Based Compensation of MXN382 Mil. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current Stock Based Compensation is MXN382 Mil. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current Stock Based Compensation is MXN382 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.

Key valuation signals for MEX:MEDP:

  • Stock Based Compensation: MXN382 Mil
  • GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medpace Holdings Business Description

Other Exchanges MEDP:USA01P:Germany
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score

Get the complete analysis for MEX:MEDP

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN7,022.03
Price
MXN6,131.53
GF Value